probucol has been researched along with Diabetes Mellitus in 9 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Both, the durable polymer zotarolimus-eluting stent (DP-ZES), the first DES to gain FDA-approval for specific use in patients with diabetes mellitus, and the polymer-free sirolimus- and probucol-eluting stent (PF-SES), with a unique design that enables effective drug release without the need of a polymer offer the potential to enhance clinical long-term outcomes especially in patients with diabetes mellitus." | 5.41 | Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy ( Aytekin, A; Cassese, S; Coughlan, JJ; Ibrahim, T; Joner, M; Kastrati, A; Kessler, T; Koch, T; Koppara, T; Kufner, S; Laugwitz, KL; Lenz, T; Schunkert, H; Wiebe, J; Xhepa, E, 2021) |
| "Probucol (PB) is a lipophilic drug used for hypercholesterolemia and possesses desirable antidiabetic effects such as antioxidant and cell protective effects." | 1.48 | Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses. ( Al-Salami, H; Arfuso, F; Goločorbin-Kon, S; Mikov, M; Mooranian, A; Stojanovic, G; Zamani, N, 2018) |
| "Probucol (PB) is a highly lipophilic, antihyperlipidemic drug with potential antidiabetic effects." | 1.42 | The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. ( Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, T | 1 |
| Lenz, T | 1 |
| Joner, M | 1 |
| Xhepa, E | 1 |
| Koppara, T | 1 |
| Wiebe, J | 1 |
| Coughlan, JJ | 1 |
| Aytekin, A | 1 |
| Ibrahim, T | 1 |
| Kessler, T | 1 |
| Cassese, S | 1 |
| Laugwitz, KL | 1 |
| Schunkert, H | 1 |
| Kastrati, A | 1 |
| Kufner, S | 1 |
| Mooranian, A | 3 |
| Zamani, N | 2 |
| Mikov, M | 2 |
| Goločorbin-Kon, S | 2 |
| Stojanovic, G | 2 |
| Arfuso, F | 3 |
| Al-Salami, H | 3 |
| Lankin, V | 1 |
| Konovalova, G | 1 |
| Tikhaze, A | 1 |
| Shumaev, K | 1 |
| Kumskova, E | 1 |
| Viigimaa, M | 1 |
| Negrulj, R | 1 |
| Stocker, R | 1 |
| Wautier, JL | 1 |
| Zoukourian, C | 1 |
| Chappey, O | 1 |
| Wautier, MP | 1 |
| Guillausseau, PJ | 1 |
| Cao, R | 1 |
| Hori, O | 1 |
| Stern, D | 1 |
| Schmidt, AM | 1 |
| Ichikawa, K | 1 |
| Yoshinari, M | 1 |
| Iwase, M | 1 |
| Wakisaka, M | 1 |
| Doi, Y | 1 |
| Iino, K | 1 |
| Yamamoto, M | 1 |
| Fujishima, M | 1 |
| Babiy, AV | 1 |
| Gebicki, JM | 1 |
| Sullivan, DR | 1 |
| Willey, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis[NCT00598533] | Phase 4 | 3,002 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for probucol and Diabetes Mellitus
| Article | Year |
|---|---|
Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Topics: Animals; Atherosclerosis; Diabetes Mellitus; Humans; Hypoglycemic Agents; Probucol | 2009 |
1 trial available for probucol and Diabetes Mellitus
| Article | Year |
|---|---|
Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; Female; | 2021 |
7 other studies available for probucol and Diabetes Mellitus
| Article | Year |
|---|---|
Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses.
Topics: Alginates; Animals; Antioxidants; Capsules; Cell Survival; Diabetes Mellitus; Drug Carriers; Humans; | 2018 |
Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment.
Topics: Alginates; Animals; Antioxidants; Bile Acids and Salts; Capsules; Cell Line; Diabetes Mellitus; Drug | 2019 |
The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus; Female; Glucose; Humans; Lipid Peroxidation | 2014 |
The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.
Topics: Animals; Anticholesteremic Agents; Cell Line; Cell Survival; Diabetes Mellitus; Drug Compounding; Dr | 2015 |
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.
Topics: Adult; Albumins; Animals; Antioxidants; Capillary Permeability; Cattle; Cells, Cultured; Diabetes Me | 1996 |
Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients.
Topics: Albumins; Antioxidants; Catalase; Cells, Cultured; Diabetes Mellitus; Flow Cytometry; Glycation End | 1998 |
Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation.
Topics: Adult; Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Female; Glycosylation; Humans; L | 1992 |